RS67519B1 - Zamenska terapija plazminogenom za nedostatak plazminogena - Google Patents

Zamenska terapija plazminogenom za nedostatak plazminogena

Info

Publication number
RS67519B1
RS67519B1 RS20251224A RSP20251224A RS67519B1 RS 67519 B1 RS67519 B1 RS 67519B1 RS 20251224 A RS20251224 A RS 20251224A RS P20251224 A RSP20251224 A RS P20251224A RS 67519 B1 RS67519 B1 RS 67519B1
Authority
RS
Serbia
Prior art keywords
plasminogen
activity
subject
deficiency
glu
Prior art date
Application number
RS20251224A
Other languages
English (en)
Serbian (sr)
Inventor
Martin Robitaille
Karen Thibaudeau
Pierre Laurin
Stacy Plum
Original Assignee
Kedrion Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kedrion Biopharma Inc filed Critical Kedrion Biopharma Inc
Publication of RS67519B1 publication Critical patent/RS67519B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20251224A 2015-11-03 2016-11-03 Zamenska terapija plazminogenom za nedostatak plazminogena RS67519B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency
EP16861682.9A EP3370760B1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
RS67519B1 true RS67519B1 (sr) 2025-12-31

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20251224A RS67519B1 (sr) 2015-11-03 2016-11-03 Zamenska terapija plazminogenom za nedostatak plazminogena

Country Status (24)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
DK (1) DK3370760T3 (enExample)
ES (1) ES3055824T3 (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
LT (1) LT3370760T (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
PL (1) PL3370760T3 (enExample)
PT (1) PT3370760T (enExample)
RS (1) RS67519B1 (enExample)
RU (1) RU2736831C2 (enExample)
SI (1) SI3370760T1 (enExample)
SM (1) SMT202500451T1 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CN115845037A (zh) * 2015-12-18 2023-03-28 泰伦基国际有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US11338022B2 (en) 2015-12-18 2022-05-24 Talengen International Limited Method for preventing and treating angiocardiopathy
US12011455B2 (en) 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
US11129880B2 (en) * 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
TW201822805A (zh) * 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
EP3556385A4 (en) 2016-12-15 2020-12-30 Talengen International Limited PROCESS FOR ALLEGING HEART DISEASE
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
US11219669B2 (en) 2016-12-15 2022-01-11 Talengen International Limited Method for preventing and treating liver fibrosis
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
US11938172B2 (en) 2017-06-19 2024-03-26 Talengen International Limited Method for regulating and controlling GLP-1/GLP-1R and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
EP3914288A1 (en) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen for treating and preventing microthrombosis
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
WO1994018315A1 (en) * 1993-02-05 1994-08-18 Vascular Laboratories, Inc. Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2008026999A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Candidates against infection
EP2451835A1 (en) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑

Also Published As

Publication number Publication date
US11291711B2 (en) 2022-04-05
RU2018120182A (ru) 2019-12-04
AU2016347863B2 (en) 2023-11-09
SMT202500451T1 (it) 2026-01-12
ES3055824T3 (en) 2026-02-16
FI3370760T3 (fi) 2025-12-05
IL258913A (en) 2018-06-28
ZA201802820B (en) 2019-07-31
CA3002915C (en) 2024-01-16
IL258913B (en) 2021-12-01
CN108289935A (zh) 2018-07-17
JP6878423B2 (ja) 2021-05-26
SI3370760T1 (sl) 2026-02-27
CA3002915A1 (en) 2017-05-11
RU2018120182A3 (enExample) 2020-04-27
BR112018008965A8 (pt) 2019-02-26
KR20180083348A (ko) 2018-07-20
EP3370760A4 (en) 2019-06-26
US20190231854A1 (en) 2019-08-01
LT3370760T (lt) 2025-12-29
AU2016347863A1 (en) 2018-06-07
PL3370760T3 (pl) 2026-03-23
KR102821400B1 (ko) 2025-06-18
WO2017077380A1 (en) 2017-05-11
MX2018005588A (es) 2018-11-09
DK3370760T3 (da) 2025-12-22
NZ742657A (en) 2024-04-26
BR112018008965A2 (pt) 2018-11-21
JP2018533589A (ja) 2018-11-15
TWI801331B (zh) 2023-05-11
PT3370760T (pt) 2025-12-03
EP3370760B1 (en) 2025-10-01
TW201722463A (zh) 2017-07-01
MY199581A (en) 2023-11-07
RU2736831C2 (ru) 2020-11-20
EP3370760A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
TWI801331B (zh) 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
Pitchumoni et al. Systemic complications of acute pancreatitis.
Bosch et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial
JP5037331B2 (ja) 出血性障害の処置のための第ｉｘａ因子
Roldán et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis
US20220160847A1 (en) Method of preventing and/or treating a plurality of diseases
US20090018082A1 (en) Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma
Picciotto et al. The organ handling of soluble klotho in humans
Shapiro et al. How I treat type 1 plasminogen deficiency
Vu et al. A review of alkaline phosphatase in preventing systemic inflammation after cardiac surgery
Peus et al. Coagulation factor V gene mutation associated with activated protein C resistance leading to recurrent thrombosis, leg ulcers, and lymphedema: successful treatment with intermittent compression
JP2009520696A (ja) 出血性ショックおよびその続発症を治療するための製剤
Tungtrongchitr et al. The effect of cigarette smoking on ceruloplasmin and C3 complement: risk of cardiovascular disease (atherosclerosis).
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Maes et al. In Transfusion-dependent Thalassemia, Increased Iron Overload is Associated with Lower Serum Alpha-klotho, Which is Strongly Associated with Lower Total and Ionized Calcium Concentrations
Pomero et al. Direct oral anticoagulants in factor VII deficiency patient
Saheb Ridha et al. In individuals with unstable angina, insulin resistance has multiple connecting arms.
Moustafa et al. In transfusion-dependent thalassemia, increased iron overload is associated with lower serum alpha-klotho, which is strongly associated with lower total and ionized calcium concentrations.
JP4348254B2 (ja) 肝硬変進展抑制用食品及び薬剤
Nath et al. Association of Circulating Matrix Metalloproteinase-9 and the Risk of Coronary Heart Disease in Young Smokers
Mari Gene-environment interactions and vascular risk in the elderly
Martins e Silva The 4th International Symposium on Clinical Haemorheology: Report and Abstracts
I–MD A STUDY OF PLASMA FIBRINOGEN LEVELS IN STROKE
Tálosi Department of Pediatrics, Albert Szent-Gyorgyi Medical and Pharmacological Center, University of Szeged, Hungary
ADANIR et al. The Levels of Von Willebrand Factor in Adult Patients with Familial Mediterranean Fever and it is Relationship with Platelet Activation